That's the finding of a new working paper from Yale and London Business School researchers, who determined that 5% more drugs would become available each year if not for what they refer to as "killer acquisitions."
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,